Nupur Sinha, MD
Pulmonary Disease · Monterey
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 19
- 3 carriers
- Offices
- 3
Offices
3 locations · Community Hospital of the Monterey Peninsula · Cep America - Intensivists PC · County of Santa Clara
Looking this up.
Hospitals listed: Community Hospital of the Monterey Peninsula · El Camino Health · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
19 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sinha’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
19 of 19 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
California Medical Board record
Licence A136981 · Current
Licensed to practise in California · since 2015 · expires 2028-12-31 · Kanpur University, G. S. V. M. Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$146,327
Medicare paid this office $146,327 for 449 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 233 | $94,508 | $167 |
| Return visit (30+ min) | 94 | $11,243 | $89 |
| Critical care, each additional 30 minutes | 64 | $6,124 | $85 |
| New patient visit (45+ min) | 47 | $6,027 | $128 |
| Short return visit (20+ min) | 58 | $4,692 | $72 |
See all 20 services
| Critical care, first 30-74 minutes | 233 | $94,508 | $167 |
| Return visit (30+ min) | 94 | $11,243 | $89 |
| Critical care, each additional 30 minutes | 64 | $6,124 | $85 |
| New patient visit (45+ min) | 47 | $6,027 | $128 |
| Short return visit (20+ min) | 58 | $4,692 | $72 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 48 | $3,387 | $65 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 26 | $3,035 | $89 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 23 | $2,562 | $111 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | $1,316 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,222 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 11 | $1,170 | $106 |
| Insertion of artery tube for blood sampling or infusion through skin | 29 | $1,040 | $36 |
| Ultrasonic guidance for blood vessel access | 48 | $807 | $11 |
| Test to determine lung volumes using sensors | 81 | $772 | $9 |
| Test for exercise-induced lung stress | 21 | $698 | $27 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 74 | $602 | $8 |
| Test to examine how well the lungs exchange gases | 82 | $578 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 14 | $193 | $10 |
| Inhalation treatment for airway obstruction or sputum production | 26 | $179 | $7 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 12 | $1 | None |
Who their Medicare patients are
449 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 13% · Women 55% · Also on Medicaid 39% · Health risk score 2.35. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Heart failure 47% · COPD 45% · Coronary heart disease 44% · Diabetes 43% · Atrial fibrillation 40% · Chronic kidney disease 39% · Depression 29% · Stroke 19% · Dementia 18% · Cancer 15%.
The office billed $551,466, Medicare allowed $191,482 and paid $146,327; for 1,593 services of 45 kinds; $165 of it was for drugs given in the office and $146,162 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 449 | 1,593 | 75 | 2.35 | $551,466 | $146,327 |
| 2023 | 470 | 1,622 | 74 | 2.24 | $623,005 | $173,646 |
| 2022 | 300 | 1,148 | 76 | 2.24 | $590,571 | $159,446 |
| 2021 | 447 | 1,630 | 74 | 2.21 | $523,951 | $170,361 |
| 2020 | 443 | 1,868 | 75 | 2.03 | $600,209 | $193,674 |
| 2019 | 414 | 1,785 | 76 | 2.03 | $561,114 | $170,804 |
| 2018 | 407 | 1,801 | 76 | 2.06 | $557,710 | $175,266 |
| 2017 | 343 | 1,585 | 75 | 1.86 | $455,327 | $141,397 |
| 2016 | 346 | 1,635 | 75 | 1.87 | $527,215 | $167,792 |
| 2015 | 88 | 296 | 72 | 1.92 | $116,313 | $37,439 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 20 services
| Critical care, first 30-74 minutes | 236 | $106,401 | $181 |
| Critical care, each additional 30 minutes | 95 | $12,909 | $90 |
| Return visit (30+ min) | 80 | $10,203 | $109 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $7,269 | $101 |
| New patient visit (45+ min) | 45 | $6,261 | $139 |
| Long return visit (40+ min) | 25 | $4,029 | $155 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 34 | $3,509 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,256 | $148 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 44 | $3,175 | $71 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 20 | $2,369 | $118 |
| Short return visit (20+ min) | 22 | $1,731 | $79 |
| Insertion of artery tube for blood sampling or infusion through skin | 30 | $1,151 | $37 |
| Ultrasonic guidance for blood vessel access | 49 | $802 | $12 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 20 | $736 | $35 |
| Test to determine lung volumes using sensors | 59 | $594 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 59 | $500 | $8 |
| Test to examine how well the lungs exchange gases | 58 | $432 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 19 | $216 | $10 |
| Inhalation treatment for airway obstruction or sputum production | 16 | $132 | $8 |
| Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 17 | $1 | None |
2022: 15 services
| Critical care, first 30-74 minutes | 221 | $127,049 | $185 |
| Critical care, each additional 30 minutes | 80 | $10,348 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $4,094 | $87 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 27 | $3,581 | $105 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 21 | $2,758 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,357 | $168 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 21 | $1,576 | $72 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,397 | $107 |
| Insertion of artery tube for blood sampling or infusion through skin | 21 | $771 | $37 |
| Return visit (30+ min) | 14 | $760 | $54 |
| Ultrasonic guidance for blood vessel access | 30 | $449 | $12 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 21 | $298 | $11 |
| Test to determine lung volumes using sensors | 18 | $177 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 17 | $142 | $8 |
| Test to examine how well the lungs exchange gases | 17 | $123 | $7 |
2021: 21 services
| Critical care, first 30-74 minutes | 179 | $85,354 | $184 |
| Return visit (30+ min) | 187 | $32,986 | $105 |
| Critical care, each additional 30 minutes | 93 | $12,893 | $93 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 34 | $4,379 | $102 |
| New patient visit (60+ min) | 23 | $4,099 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $3,342 | $88 |
| Long return visit (40+ min) | 20 | $3,180 | $151 |
| New patient visit (45+ min) | 19 | $2,773 | $146 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,679 | $99 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 21 | $2,458 | $112 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 15 | $1,793 | $120 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 25 | $1,789 | $72 |
| Short return visit (20+ min) | 23 | $1,622 | $68 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 15 | $836 | $31 |
| Insertion of artery tube for blood sampling or infusion through skin | 21 | $829 | $38 |
| Test to determine lung volumes using sensors | 73 | $753 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 72 | $602 | $8 |
| Test to examine how well the lungs exchange gases | 75 | $581 | $7 |
| Ultrasonic guidance for blood vessel access | 32 | $555 | $12 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 26 | $383 | $11 |
| Test to measure expiratory airflow and volume | 13 | $107 | $7 |
2020: 27 services
| Critical care, first 30-74 minutes | 162 | $89,440 | $189 |
| Return visit (30+ min) | 157 | $19,624 | $84 |
| Long return visit (40+ min) | 118 | $18,579 | $111 |
| Critical care, each additional 30 minutes | 93 | $18,119 | $95 |
| New patient visit (60+ min) | 72 | $12,608 | $175 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,316 | $118 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 24 | $2,850 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,497 | $89 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 34 | $2,495 | $67 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 30 | $2,194 | $73 |
| Telephone medical discussion with physician, 21-30 minutes | 23 | $1,644 | $69 |
| Pneumococcal vaccine, 23-valent | 15 | $1,591 | $106 |
| Short return visit (20+ min) | 15 | $937 | $55 |
| Insertion of artery tube for blood sampling or infusion through skin | 24 | $905 | $38 |
| Influenza vaccine split virus, preservative free | 16 | $903 | $56 |
| Telephone medical discussion with physician, 11-20 minutes | 18 | $880 | $49 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 17 | $776 | $31 |
| Test to determine lung volumes using sensors | 60 | $678 | $11 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 59 | $673 | $11 |
| Ultrasonic guidance for blood vessel access | 38 | $644 | $12 |
| Test to examine how well the lungs exchange gases | 60 | $502 | $8 |
| Administration of pneumococcal vaccine | 19 | $320 | $17 |
| Administration of influenza virus vaccine | 16 | $305 | $18 |
| Telephone medical discussion with physician, 5-10 minutes | 13 | $255 | $20 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $233 | $11 |
| Test to measure expiratory airflow and volume | 11 | $81 | $7 |
| Exam of lung airways using an endoscope | 11 | $12 | $1 |
2019: 24 services
| Critical care, first 30-74 minutes | 151 | $76,047 | $179 |
| Return visit (30+ min) | 162 | $25,148 | $84 |
| Critical care, each additional 30 minutes | 95 | $18,274 | $91 |
| New patient visit (60+ min) | 58 | $9,616 | $166 |
| Long return visit (40+ min) | 47 | $7,276 | $121 |
| Short return visit (20+ min) | 61 | $3,682 | $46 |
| Pneumococcal vaccine, 13-valent | 16 | $3,336 | $209 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 34 | $2,477 | $71 |
| Pneumococcal vaccine, 23-valent | 22 | $2,182 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,987 | $86 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 13 | $1,637 | $117 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 18 | $1,587 | $84 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 27 | $1,386 | $50 |
| Biopsy of lobe of lung using an endoscope, 1 lobe | 11 | $1,261 | $115 |
| Influenza vaccine split virus, preservative free | 21 | $1,087 | $52 |
| Smoking and tobacco use intensive counseling, more than 10 minutes | 19 | $976 | $30 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 67 | $725 | $11 |
| Test to determine lung volumes using sensors | 64 | $653 | $10 |
| Administration of pneumococcal vaccine | 36 | $635 | $18 |
| Insertion of artery tube for blood sampling or infusion through skin | 16 | $632 | $37 |
| Ultrasonic guidance for blood vessel access | 39 | $542 | $12 |
| Test to examine how well the lungs exchange gases | 67 | $506 | $8 |
| Administration of influenza virus vaccine | 21 | $370 | $18 |
| Exam of lung airways using an endoscope | 15 | $18 | $1 |
2018: 21 services
| Critical care, first 30-74 minutes | 166 | $84,206 | $178 |
| Critical care, each additional 30 minutes | 105 | $19,728 | $90 |
| Return visit (30+ min) | 131 | $19,103 | $80 |
| Long return visit (40+ min) | 70 | $12,455 | $106 |
| New patient visit (60+ min) | 43 | $6,947 | $162 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 38 | $4,277 | $97 |
| Short return visit (20+ min) | 65 | $3,971 | $52 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 47 | $3,867 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 17 | $2,808 | $165 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 21 | $2,511 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $1,700 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,661 | $59 |
| Pneumococcal vaccine, 23-valent | 11 | $1,161 | $106 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 81 | $786 | $10 |
| Test to determine lung volumes using sensors | 83 | $770 | $9 |
| Ultrasonic guidance for blood vessel access | 48 | $694 | $12 |
| Influenza vaccine split virus, preservative free | 12 | $623 | $52 |
| Test to examine how well the lungs exchange gases | 82 | $571 | $7 |
| Insertion of artery tube for blood sampling or infusion through skin | 14 | $504 | $36 |
| Administration of pneumococcal vaccine | 18 | $392 | $22 |
| Administration of influenza virus vaccine | 11 | $239 | $22 |
2017: 23 services
| Critical care, first 30-74 minutes | 123 | $59,194 | $180 |
| Long return visit (40+ min) | 94 | $17,296 | $106 |
| Return visit (30+ min) | 98 | $12,493 | $78 |
| Critical care, each additional 30 minutes | 56 | $11,636 | $90 |
| New patient visit (60+ min) | 69 | $10,753 | $156 |
| Short return visit (20+ min) | 42 | $3,017 | $58 |
| Pneumococcal vaccine, 13-valent | 16 | $2,987 | $187 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 26 | $2,745 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,629 | $164 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 34 | $2,302 | $64 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 18 | $2,057 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,936 | $59 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 93 | $994 | $11 |
| Influenza vaccine split virus, preservative free | 20 | $961 | $48 |
| Test to determine lung volumes using sensors | 94 | $948 | $10 |
| Insertion of artery tube for blood sampling or infusion through skin | 19 | $873 | $42 |
| Test to examine how well the lungs exchange gases | 96 | $717 | $7 |
| Administration of pneumococcal vaccine | 24 | $646 | $27 |
| Ultrasonic guidance for blood vessel access | 35 | $575 | $12 |
| Administration of influenza virus vaccine | 19 | $511 | $27 |
| Test to determine lung volumes using gas dilution or washout | 12 | $121 | $10 |
| Exam of lung airways using an endoscope | 18 | $47 | $2 |
| Test to measure oxygen level in blood using ear or finger device multiple times | 11 | $46 | $4 |
2016: 20 services
| Critical care, first 30-74 minutes | 168 | $82,369 | $179 |
| Critical care, each additional 30 minutes | 92 | $22,143 | $90 |
| Long return visit (40+ min) | 68 | $15,946 | $109 |
| New patient visit (60+ min) | 95 | $15,665 | $165 |
| Return visit (30+ min) | 51 | $5,668 | $85 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 38 | $4,140 | $92 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 32 | $3,159 | $99 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 27 | $2,583 | $89 |
| Pneumococcal vaccine, 13-valent | 12 | $2,114 | $176 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,440 | $111 |
| Insertion of artery tube for blood sampling or infusion through skin | 30 | $1,251 | $42 |
| Short return visit (20+ min) | 13 | $899 | $60 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 75 | $778 | $10 |
| Test to determine lung volumes using sensors | 76 | $758 | $10 |
| Ultrasonic guidance for blood vessel access | 49 | $682 | $12 |
| Administration of influenza virus vaccine | 24 | $663 | $27 |
| Influenza vaccine split virus, preservative free | 16 | $657 | $41 |
| Test to examine how well the lungs exchange gases | 76 | $567 | $7 |
| Administration of pneumococcal vaccine | 15 | $398 | $27 |
| Exam of lung airways using an endoscope | 11 | $24 | $2 |
2015: 5 services
| Critical care, first 30-74 minutes | 52 | $26,709 | $177 |
| Critical care, each additional 30 minutes | 17 | $3,261 | $91 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 11 | $118 | $11 |
| Test to determine lung volumes using sensors | 11 | $112 | $10 |
| Test to examine how well the lungs exchange gases | 11 | $83 | $8 |
Medicaid work
$12,583 in 2024
Medicaid paid $12,583 for 176 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 176 | $12,583 |
| 2024 | 176 | 1 | 15 | $12,583 |
| 2023 | 173 | 2 | 20 | $15,272 |
| 2022 | 216 | 1 | 19 | $21,975 |
| 2021 | 154 | 2 | 14 | $14,012 |
| 2020 | 115 | 3 | 23 | $7,535 |
| 2019 | 39 | 1 | 14 | $2,482 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 143 | $13,943 |
| Return visit (30+ min) | 30 | $1,329 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 216 | $21,975 |
2021
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 90 | $9,363 |
| Return visit (30+ min) | 64 | $4,648 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 87 | $5,803 |
| Return visit (30+ min) | 13 | $907 |
| Critical care, evaluation and management of the critically ill or critically injured patient; each additional 30 minutes (List separately in addition to code for primary service) | 15 | $825 |
2019
| Return visit (30+ min) | 39 | $2,482 |
Drugs they prescribed that Part D paid
$258,073
Pharmacies billed $258,073 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,007) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
431 generic and 576 brand-name prescriptions · $258,073 in drug cost · 57 antibiotic prescriptions to 31 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Trelegy Ellipta | 149 | $109,064 | $732 |
| Anoro Ellipta | 84 | $44,016 | $524 |
| Breo Ellipta | 75 | $31,366 | $418 |
| Combivent Respimat | 27 | $17,081 | $633 |
| Albuterol Sulfate Hfa | 185 | $7,782 | $42 |
See all 16 drugs
| Trelegy Ellipta | 149 | $109,064 | $732 |
| Anoro Ellipta | 84 | $44,016 | $524 |
| Breo Ellipta | 75 | $31,366 | $418 |
| Combivent Respimat | 27 | $17,081 | $633 |
| Albuterol Sulfate Hfa | 185 | $7,782 | $42 |
| Ventolin Hfa | 40 | $2,593 | $65 |
| Breyna | 15 | $2,567 | $171 |
| Wixela Inhub | 13 | $2,233 | $172 |
| Fluticasone-Salmeterol | 17 | $2,081 | $122 |
| Montelukast | 97 | $1,109 | $11 |
| Famotidine | 41 | $411 | $10 |
| Azithromycin | 20 | $331 | $17 |
| Fluticasone Propionate | 35 | $225 | $6 |
| Doxycycline Hyclate | 24 | $167 | $7 |
| Prednisone | 29 | $144 | $5 |
| Omeprazole | 28 | $116 | $4 |
Year by year
| 2024 | 1,007 | 140 | 0% (0) | 57% | $258,073 |
| 2023 | 257 | 66 | 0% (0) | 65% | $73,709 |
| 2022 | 637 | 129 | 0% (0) | 70% | $398,756 |
| 2021 | 1,702 | 203 | None | 61% | $894,610 |
| 2020 | 1,755 | 204 | 0% (0) | 62% | $659,868 |
| 2019 | 1,499 | 162 | 0% (0) | 60% | $620,265 |
| 2018 | 1,309 | 144 | 0% (0) | 58% | $531,676 |
| 2017 | 1,203 | 129 | None | 55% | $306,285 |
| 2016 | 534 | 68 | 0% (0) | 54% | $98,744 |
| 2015 | 16 | None | 0% (0) | 100% | $3,183 |
| 2014 | 294 | 47 | 0% (0) | 83% | $53,910 |
| 2013 | 329 | 54 | 0% (0) | 87% | $66,904 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Trelegy Ellipta | 36 | $27,240 | $757 |
| Breo Ellipta | 30 | $15,512 | $517 |
| Anoro Ellipta | 25 | $13,101 | $524 |
| Albuterol Sulfate Hfa | 41 | $1,772 | $43 |
| Ventolin Hfa | 19 | $1,248 | $66 |
| Montelukast | 15 | $345 | $23 |
| Omeprazole | 15 | $221 | $15 |
| Prednisone | 14 | $69 | $5 |
2022: 11 drugs
| Anoro Ellipta | 118 | $81,059 | $687 |
| Trelegy Ellipta | 82 | $69,256 | $845 |
| Spiriva Respimat | 17 | $22,512 | $1,324 |
| Incruse Ellipta | 35 | $21,619 | $618 |
| Breo Ellipta | 41 | $19,805 | $483 |
| Symbicort | 12 | $8,950 | $746 |
| Flovent Hfa | 16 | $5,401 | $338 |
| Albuterol Sulfate Hfa | 59 | $2,680 | $45 |
| Azelastine-Fluticasone | 12 | $2,625 | $219 |
| Montelukast | 108 | $2,441 | $23 |
| Ventolin Hfa | 22 | $1,533 | $70 |
2021: 26 drugs
| Ofev | 13 | $157,535 | $12,118 |
| Anoro Ellipta | 207 | $139,404 | $673 |
| Trelegy Ellipta | 181 | $132,677 | $733 |
| Ambrisentan | 12 | $78,646 | $6,554 |
| Spiriva Respimat | 70 | $60,874 | $870 |
| Breo Ellipta | 77 | $39,587 | $514 |
| Incruse Ellipta | 50 | $25,326 | $507 |
| Symbicort | 32 | $23,122 | $723 |
| Flovent Hfa | 32 | $15,256 | $477 |
| Advair Diskus | 22 | $11,112 | $505 |
| Atrovent Hfa | 13 | $9,306 | $716 |
| Albuterol Sulfate Hfa | 182 | $8,906 | $49 |
| Bevespi Aerosphere | 20 | $8,266 | $413 |
| Voriconazole | 18 | $7,729 | $429 |
| Montelukast | 225 | $4,523 | $20 |
| Ventolin Hfa | 66 | $4,313 | $65 |
| Fluticasone-Salmeterol | 24 | $3,747 | $156 |
| Azelastine | 41 | $2,842 | $69 |
| Proair Hfa | 14 | $1,557 | $111 |
| Levalbuterol Tartrate Hfa | 20 | $1,067 | $53 |
| Omeprazole | 58 | $777 | $13 |
| Fluticasone Propionate | 32 | $625 | $20 |
| Esomeprazole Magnesium | 22 | $617 | $28 |
| Doxycycline Hyclate | 31 | $568 | $18 |
| Prednisone | 79 | $431 | $5 |
| Azithromycin | 15 | $103 | $7 |
2020: 29 drugs
| Anoro Ellipta | 233 | $152,788 | $656 |
| Adempas | 14 | $145,380 | $10,384 |
| Trelegy Ellipta | 92 | $68,810 | $748 |
| Spiriva Respimat | 101 | $63,864 | $632 |
| Breo Ellipta | 115 | $49,886 | $434 |
| Incruse Ellipta | 67 | $31,159 | $465 |
| Symbicort | 51 | $29,537 | $579 |
| Flovent Hfa | 32 | $14,465 | $452 |
| Daliresp | 19 | $11,467 | $604 |
| Advair Diskus | 17 | $10,249 | $603 |
| Spiriva | 12 | $5,837 | $486 |
| Wixela Inhub | 19 | $5,595 | $294 |
| Ventolin Hfa | 84 | $5,261 | $63 |
| Albuterol Sulfate Hfa | 109 | $5,180 | $48 |
| Atrovent Hfa | 11 | $4,668 | $424 |
| Montelukast | 274 | $4,648 | $17 |
| Azelastine | 58 | $3,074 | $53 |
| Fluticasone-Salmeterol | 22 | $2,652 | $121 |
| Proair Hfa | 31 | $2,205 | $71 |
| Fluticasone Propionate | 73 | $1,361 | $19 |
| Levalbuterol Tartrate Hfa | 22 | $1,253 | $57 |
| Ipratropium | 11 | $423 | $38 |
| Omeprazole | 40 | $408 | $10 |
| Esomeprazole Magnesium | 13 | $395 | $30 |
| Prednisone | 59 | $362 | $6 |
| Doxycycline Hyclate | 18 | $223 | $12 |
| Furosemide | 20 | $151 | $8 |
| Pantoprazole | 18 | $138 | $8 |
| Azithromycin | 12 | $104 | $9 |
2019: 28 drugs
| Letairis | 13 | $134,832 | $10,372 |
| Anoro Ellipta | 227 | $132,341 | $583 |
| Adempas | 11 | $115,959 | $10,542 |
| Spiriva Respimat | 85 | $45,049 | $530 |
| Breo Ellipta | 63 | $29,292 | $465 |
| Incruse Ellipta | 63 | $28,460 | $452 |
| Symbicort | 44 | $20,787 | $472 |
| Trelegy Ellipta | 36 | $20,122 | $559 |
| Flovent Hfa | 41 | $13,815 | $337 |
| Spiriva | 18 | $8,215 | $456 |
| Atrovent Hfa | 18 | $7,224 | $401 |
| Combivent Respimat | 16 | $6,757 | $422 |
| Ventolin Hfa | 102 | $6,473 | $63 |
| Bevespi Aerosphere | 15 | $5,399 | $360 |
| Montelukast | 231 | $4,800 | $21 |
| Pulmicort Flexhaler | 15 | $3,732 | $249 |
| Proair Hfa | 29 | $2,328 | $80 |
| Albuterol Sulfate Hfa | 35 | $1,964 | $56 |
| Fluticasone-Salmeterol | 16 | $1,801 | $113 |
| Azelastine | 33 | $1,577 | $48 |
| Fluticasone Propionate | 72 | $1,475 | $20 |
| Doxycycline Hyclate | 26 | $519 | $20 |
| Omeprazole | 42 | $511 | $12 |
| Prednisone | 73 | $321 | $4 |
| Amoxicillin-Clavulanate Potass | 18 | $213 | $12 |
| Famotidine | 13 | $186 | $14 |
| Furosemide | 21 | $186 | $9 |
| Azithromycin | 12 | $67 | $6 |
2018: 22 drugs
| Adempas | 14 | $126,955 | $9,068 |
| Anoro Ellipta | 243 | $126,321 | $520 |
| Letairis | 11 | $109,945 | $9,995 |
| Spiriva Respimat | 54 | $31,542 | $584 |
| Incruse Ellipta | 55 | $25,875 | $470 |
| Advair Diskus | 29 | $21,481 | $741 |
| Flovent Hfa | 45 | $14,266 | $317 |
| Breo Ellipta | 31 | $13,668 | $441 |
| Stiolto Respimat | 23 | $11,186 | $486 |
| Spiriva | 20 | $10,767 | $538 |
| Ventolin Hfa | 99 | $6,295 | $64 |
| Symbicort | 14 | $4,919 | $351 |
| Montelukast | 224 | $4,525 | $20 |
| Proair Hfa | 56 | $3,853 | $69 |
| Azelastine | 34 | $1,662 | $49 |
| Fluticasone Propionate | 80 | $1,204 | $15 |
| Fluticasone-Salmeterol | 11 | $1,053 | $96 |
| Doxycycline Hyclate | 34 | $439 | $13 |
| Omeprazole | 31 | $400 | $13 |
| Prednisone | 62 | $287 | $5 |
| Furosemide | 27 | $137 | $5 |
| Famotidine | 13 | $126 | $10 |
2017: 22 drugs
| Spiriva Respimat | 93 | $41,921 | $451 |
| Anoro Ellipta | 89 | $32,913 | $370 |
| Invega Sustenna | 12 | $30,250 | $2,521 |
| Incruse Ellipta | 61 | $22,321 | $366 |
| Advair Diskus | 41 | $20,296 | $495 |
| Breo Ellipta | 52 | $18,359 | $353 |
| Spiriva | 28 | $15,004 | $536 |
| Symbicort | 30 | $10,142 | $338 |
| Flovent Hfa | 32 | $7,696 | $241 |
| Proair Hfa | 81 | $5,414 | $67 |
| Montelukast | 228 | $3,492 | $15 |
| Ventolin Hfa | 55 | $3,042 | $55 |
| Flovent Diskus | 14 | $2,641 | $189 |
| Arnuity Ellipta | 12 | $2,515 | $210 |
| Azelastine | 52 | $2,059 | $40 |
| Fluticasone Propionate | 51 | $763 | $15 |
| Omeprazole | 35 | $384 | $11 |
| Prednisone | 78 | $370 | $5 |
| Amoxicillin-Clavulanate Potass | 17 | $153 | $9 |
| Azithromycin | 17 | $107 | $6 |
| Furosemide | 12 | $78 | $6 |
| Sertraline | 11 | $74 | $7 |
2016: 13 drugs
| Spiriva Respimat | 51 | $17,711 | $347 |
| Spiriva | 27 | $15,061 | $558 |
| Symbicort | 50 | $14,977 | $300 |
| Breo Ellipta | 16 | $6,399 | $400 |
| Advair Diskus | 15 | $5,771 | $385 |
| Incruse Ellipta | 20 | $5,669 | $283 |
| Anoro Ellipta | 16 | $5,054 | $316 |
| Proair Hfa | 29 | $1,801 | $62 |
| Montelukast | 109 | $1,714 | $16 |
| Ventolin Hfa | 24 | $1,251 | $52 |
| Fluticasone Propionate | 23 | $326 | $14 |
| Azithromycin | 15 | $146 | $10 |
| Prednisone | 24 | $74 | $3 |
2014: 8 drugs
| Spiriva | 86 | $25,954 | $302 |
| Advair Diskus | 31 | $10,297 | $332 |
| Flovent Hfa | 24 | $5,637 | $235 |
| Symbicort | 12 | $3,038 | $253 |
| Ventolin Hfa | 42 | $2,088 | $50 |
| Proair Hfa | 35 | $1,703 | $49 |
| Montelukast | 27 | $864 | $32 |
| Prednisone | 12 | $25 | $2 |
2013: 8 drugs
| Spiriva | 97 | $28,974 | $299 |
| Advair Diskus | 51 | $16,047 | $315 |
| Flovent Hfa | 27 | $7,324 | $271 |
| Advair Hfa | 13 | $4,177 | $321 |
| Symbicort | 13 | $3,073 | $236 |
| Proair Hfa | 28 | $1,665 | $59 |
| Ventolin Hfa | 34 | $1,586 | $47 |
| Montelukast | 26 | $1,430 | $55 |
Money from drug and device companies
$106 in 2025
| 2025 | 2 | 5 | None | $106 |
| 2024 | 4 | 13 | None | $285 |
| 2023 | 5 | 14 | None | $399 |
| 2021 | 2 | 8 | None | $159 |
| 2020 | 2 | 12 | None | $156 |
| 2019 | 2 | 5 | None | $99 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| GlaxoSmithKline | Nucala | $85 | 4 payments
|
| Insmed | Arikayce | $21 | 1 payment
|
See all 5 published payments
| Insmed | Meals · 2025-09-12 | Arikayce | $21 |
| GlaxoSmithKline | Meals · 2025-02-21 | Nucala | $21 |
| GlaxoSmithKline | Meals · 2025-01-15 | Trelegy Ellipta | $27 |
| GlaxoSmithKline | Meals · 2025-01-14 | Nucala | $21 |
| GlaxoSmithKline | Meals · 2025-01-08 | Nucala | $15 |
See earlier years (2024, 2023, 2021, 2020, 2019)
2024: $285
| GlaxoSmithKline | Nucala | $187 | 8 payments
|
| Novartis Pharmaceuticals | Xolair | $50 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $30 | 2 payments
|
| Genzyme | Dupixent | $18 | 1 payment
|
2023: $399
| GlaxoSmithKline | Nucala | $148 | 5 payments
|
| AstraZeneca Pharmaceuticals LP | Tezspire | $132 | 5 payments
|
| Sanofi-Aventis U.S. | Dupixent | $62 | 1 payment
|
| Genzyme | Dupixent | $33 | 2 payments
|
| Novartis Pharmaceuticals | Xolair | $24 | 1 payment
|
2021: $159
| GlaxoSmithKline | Trelegy Ellipta | $147 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $11 | 1 payment
|
2020: $156
| GlaxoSmithKline | Anoro Ellipta | $122 | 11 payments
|
| Actelion Pharmaceuticals US | Uptravi | $33 | 1 payment
|
2019: $99
| GlaxoSmithKline | Anoro | $88 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Bevespi Aerosphere | $11 | 1 payment
|
Professional record
- NPI
- 1720312671
- Licence
- CA A136981California A136981: Current · expires 2028-12-31
- Group
- Community Hospital of the Monterey Peninsula · Cep America - Intensivists PC · County of Santa Clara
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RP1001X (207RP1001X); Internal medicine (207R00000X); Federal specialty code 207RC0200X (207RC0200X)
- Mailing address
- 100 Wilson Rd Ste 100, Monterey, CA, 93940
- NPI first listed
- 2009-09-24
- NPI last updated
- 2023-04-28
- NPI record certified
- 2023-04-28
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1033 Los Palos Dr Ste A, Salinas, CA, 93901
This office lists an electronic records connection.